TARSUS PHARMACEUTICALS, INC. Cash and Restricted Cash
TARSUS PHARMACEUTICALS, INC. (TARS) had Cash and Restricted Cash of $206.60 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $206.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $104.19M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $186.20M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $206.60M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $104.19M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $186.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $115.29M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $99.21M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $178.35M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $97.38M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $176.21M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $181.09M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $193.71M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $224.95M 10-K · filed 2026-02-23 |
| 2023-09-30 | $226.67M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $106.77M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $66.00M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $71.66M 10-K · filed 2026-02-23 |
| 2022-09-30 | $169.49M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $245.36M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $175.01M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $171.33M 10-K · filed 2025-02-25 |
| 2021-09-30 | $183.80M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $176.74M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $156.20M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $168.15M 10-K · filed 2023-03-17 |
| 2020-09-30 | $86.35M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $53.16M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $55.91M 10-Q · filed 2021-05-11 |
| 2019-12-31 | $57.97M 10-K · filed 2022-03-14 |
| 2019-09-30 | $357.00K 10-Q · filed 2020-11-25 |
| 2018-12-31 | $2.38M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |